Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label, Multiple Dose, Two Part Dose Escalation Study of ECP-1014 as a Treatment for Patients With Solid Tumor Cancers

NCT04930354 is registered in ClinicalTrials.gov with Euclises Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04930354
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04930354 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label, Multiple Dose, Two Part Dose Escalation Study of ECP-1014 as a Treatment for Patients With Solid Tumor Cancers
Lead sponsor
Euclises Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
May 31, 2023
Completion date
December 31, 2023
Enrollment
29 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor